Clinical Schizophrenia and Related Psychoses This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The Clinical Impact of Neuroimaging in First-Episode Psychosis.
Authors: Pientka LJ, Schulz SC, Lim KO, Jasberg SG PMID: 29164931 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - November 23, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Clinical News.
Authors: Buckley PF PMID: 29035102 [PubMed - in process] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - October 17, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Exercise-associated extrapyramidal symptoms during treatment with long-acting injectable antipsychotic medications: A case report.
We report here two cases in which individuals with schizoaffective disorder treated with a long-acting injectable antipsychotic medication displayed worsening of extrapyramidal symptoms over the course of a 12-week exercise program. This can be attributed to an increase in blood flow to the depot site during exercise, accelerating the rate of absorption and bioavailability of the antipsychotic medication and subsequently increasing dopamine D2 blockade. Clinicians need to be vigilant when patients receiving long-acting injectable antipsychotic medications engage in exercise. PMID: 28777027 [PubMed - as supplied by ...
Source: Clinical Schizophrenia and Related Psychoses - August 5, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Preliminary validation of a clinical staging model in schizophrenia and related disorders.
This study aims to retrospectively explore 1) the validity of a staging model 2) the stability of staging over time, and 3) the clinical factors associated with transition to more chronic stages. Data were derived from the Genetic Risk and Outcome of Psychosis study, a large cohort study of patients with a schizophrenia spectrum disorder. We assigned patients to a clinical stage, according to methods described by McGorry in 2010, using PANSS and GAF measures at baseline and three-year follow-up. Distinction between the stages was best explained by worse symptomatic, social and neurocognitive functioning in the first ('Firs...
Source: Clinical Schizophrenia and Related Psychoses - August 5, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Characterizing Smartphone Engagement for Schizophrenia: Results of a Naturalist Mobile Health Study.
DISCUSSION: Engagement with this app for schizophrenia was overall low, but similar to prior naturalistic studies for mental health app use in other diseases. The low rate of engagement in naturalistic settings, compared to higher rates of use in clinical studies, suggests the importance of clinical involvement as one factor in driving engagement for mental health apps. Power law relationships suggest strongly skewed user engagement, with a small subset of users accounting for the majority of substantial engagements. There is a need for further research on app engagement in schizophrenia. PMID: 28777029 [PubMed - a...
Source: Clinical Schizophrenia and Related Psychoses - August 5, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

A rare presentation of auto-emasculation in a patient with schizoaffective disorder: Management with clozapine.
Authors: Birur B, Kraguljac NV PMID: 28777030 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - August 5, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

The impact of stigma on subjective well-being in people with mental disorders.
CONCLUSIONS: Positive self-concept protects the person from the harm that stigma may cause on his well-being. It especially protects positive affect, which we propose is an important resource in the recovery process. These findings have clinical and research implications. PMID: 28777031 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - August 5, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Suicidal Ideation in an Egyptian Sample of Hospitalized Patients with Acute Psychosis.
CONCLUSION: Patients with psychosis that require admission to the hospital carry a high risk of suicidal ideation and behavior. Factors like unemployment, young age and psychiatric diagnosis and severity of psychosis could be predicting factors. PMID: 28777032 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - August 5, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Pulmonary Embolism during Stuporous Episodes of Catatonia Was Found to Be the Most Frequent Cause of Preventable Death According to a State Mortality Review: 6 Deaths in 15 Years.
Authors: Puentes R, Brenzel A, de Leon J Abstract Case reports have indicated that pulmonary embolism (PE) can be associated with deaths during episodes of catatonia. A 15-year death registry in Kentucky state psychiatric hospitals was reviewed for deaths during episodes of catatonia. From 2002 to May of 2016, reports of 96 deaths at these state psychiatric hospitals were found and reviewed by the state mortality committee. The charts of the identified catatonic patients were thoroughly reviewed. All 6 deaths occurred during episodes of what Fink and Taylor would call retarded catatonia and Ungvari would c...
Source: Clinical Schizophrenia and Related Psychoses - August 5, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Chronic Schizophrenia Later Diagnosed with Anti-NMDA Receptor Encephalitis: Case Report and Review of the Literature.
Authors: Conroy MA, Finch T, Levin TT, Merkler AE, Safdieh J, Samuels S, Gordon Elliott JS PMID: 28777034 [PubMed - as supplied by publisher] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - August 5, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Clinical News.
Authors: Buckley PF PMID: 28742393 [PubMed - in process] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - July 26, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Assessment of Proteomic Measures Across Serious Psychiatric Illness.
Authors: Schulz SC, Overgaard S, Bond DJ, Kaldate R Abstract The diagnoses of serious psychiatric illnesses, such as schizophrenia, schizoaffective disorder, and bipolar disorder, rely on the subjective recall and interpretation of often overlapping symptoms, and are not based on the objective pathophysiology of the illnesses. The subjectivity of symptom reporting and interpretation contributes to the delay of accurate diagnoses and limits effective treatment of these illnesses. Proteomics, the study of the types and quantities of proteins an organism produces, may offer an objective biological approach to...
Source: Clinical Schizophrenia and Related Psychoses - July 26, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Highlights from the Biennial International Congress on Schizophrenia Research (ICOSR), March 24-March 28, 2017.
Authors: Heimer H Abstract The 2017 International Congress on Schizophrenia Research, held in San Diego, California (March 24-28, 2017), attracted over 900 attendees from 34 countries. With the gracious assistance of Congress president James Meador-Woodruff, we bring you the following reports on the prospects for new drugs to treat schizophrenia. PMID: 28742395 [PubMed - in process] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - July 26, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Valbenazine for Tardive Dyskinesia.
Authors: Freudenreich O, Remington G Abstract Tardive dyskinesia (TD) remains a clinical concern for any patient who receives an antipsychotic. While the overall risk of developing TD is lower with newer antipsychotics compared to older agents, a significant number of patients who require long-term treatment will develop TD. Recently, valbenazine (brand name Ingrezza) became the first drug to be approved by the FDA specifically for the treatment of TD. In this New Drug Review, we summarize the basic pharmacology and clinical trial results for valbenazine. Valbenazine is a modified metabolite of the vesicul...
Source: Clinical Schizophrenia and Related Psychoses - July 26, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research

Clinical News.
Authors: Buckley PF PMID: 28548575 [PubMed - in process] (Source: Clinical Schizophrenia and Related Psychoses)
Source: Clinical Schizophrenia and Related Psychoses - May 27, 2017 Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research